The androgen receptor (AR) is activated in patients with castration resistant prostate cancer (CRPC) despite low circulating levels of androgen, suggesting that intracellular signaling pathways and non-androgenic factors may contribute to AR activation. Many G-protein coupled receptors (GPCR) and their ligands are also activated in these cells indicating a role for these in CRPC. Although a cross talk has been suggested between the two pathways, yet, the identity of GPCRs which may play a role in androgen signaling, is not established yet. We demonstrate that adhesion GPCR 205, also known as GPR56, can be activated by androgens to stimulate the Rho signaling pathway, a pathway that plays an important role in prostate tumor cell metastasis.
Introduction
The AR plays a central role in the normal growth of prostate as well as its neoplastic transformation into prostate cancer (PCa) (1) . The fundamental dependence of prostate tumor on androgen signaling was established when Huggins and Hodges in 1941 demonstrated that orchiectomy in patients could reduce tumor growth (2) . Since then endocrine therapies aiming to minimize AR signaling, either by reducing androgen levels by physical or chemical means or by using AR inhibitors, constitute the primary treatment plan for PCa patients (3) . These measures however offer only a temporary relief as a more aggressive and androgen-independent form of tumor inevitably reappears, that is untreatable (4) .
Analysis of tumor samples from patients with CRPC or xenograft models demonstrate that the reasons for androgen independence include overexpression of AR in many of these tumors, mutations in AR and its alternatively spliced forms (5) , increased coactivator expression (6) and activation of AR by molecules such as cytokines or growth factors which cause stimulation of other cellular pathways that indirectly activate the AR (7, 8) .
Indeed, the release of circulating and locally synthesized factors acting via cellular receptors cause a switch of the quiescent prostate cells into an activated state causing uncontrolled cellular proliferation (9) . Among the cellular receptors that are implicated in PCa, the most prominent are the G-protein coupled receptors (GPCR) (10) . The cancerous prostate contains elevated levels of enzymes such as kallikrein 2 which control the expression of GPCR ligands (11) and it also produces increased amount of GPCR ligands such as endothelin 1 (12) , follicle stimulating hormone and lysophosphatidic acid (13) . Compared to normal prostate higher expression of various GPCRs is commonly observed in the malignant prostate such as FSH receptor (14), bradykinin 1 receptor (15) , and Endothelin 1A receptor (12) . These observations taken together strongly indicate that the GPCR system may be in the 'on' state in the malignant prostate contributing directly or indirectly to tumor growth (9) .
The classical mechanism of androgen signaling involves binding of androgen to the cytosolic AR, which dimerizes and moves into the nucleus to bind androgen response elements upstream of target genes to modulate gene expression and cause cellular proliferation (16) . This genomic signaling by androgens is mediated in hours or days. However, studies over the last decade has established that androgens also initiate rapid, non-genomic changes in target cells, which may or may not involve the nuclear AR (17) . Non-genomic signaling by androgens include activation of extracellular signal regulated kinase in Sertoli cells (18) , phosphatidyl inositol 3-kinase in osteoblasts (19) or extracellular Ca 2+ in skeletal muscle cells (20) . Androgens also initiate rapid activation of protein kinase A (PKA) in prostate cells, via a GPCR, and androgen mediated PKA activation is necessary for normal functioning of AR (17) . In fact, the activation of PKA by forskolin or other non-androgenic agents can also lead to stimulation of AR and cause transcription of androgen target genes (21) . Activation of these non-genomic pathways appear to play a key role in development of PCa and transition to CRPC (22) . Ongoing studies are attempting to identify these pathways that promote androgen signaling especially in low/no androgen backgrounds and the receptors that trigger these pathways.
In recent years, three putative membrane androgen receptors have been proposed, viz. GPRC6A (23) , OXER1 (24) and ZIP9 (25) , of which the first two are GPCRs. While GPRC6A mediates most of its functions by activating the Gq and Gi signaling pathways (26) , OXER1 functions are mediated via G i or G β/γ (24) pathways. Neither of these GPCRs are known to play a role in classical androgen signaling.
Here we identified an adhesion GPCR, GPCR 205 (GPR56) with structural similarity to the AR ligand binding domain (LBD) using a bioinformatics approach. Further, we analyzed it as a candidate for membrane androgen binding. Our results demonstrate that androgen-induced activation of GPR56, is required for complete activation of the AR. Compared to normal tissue GPR56 mRNA expression was higher in all 25 tumor samples tested. Our results provide an alternate mechanism of AR activation in PCa patients, via GPR56 and this may be exploited to aid the hormonal therapies in CRPC patients.
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Materials and methods
Cell culture
LNCaP, PC3, DU145, TM3, HEK293 and Cos-1 cell lines originating from ATCC were purchased from National Centre for Cell Science (NCCS) (Pune, India). These cells were maintained in RPMI 1640, DMEM and HAM'S F12 (Himedia, New Delhi, India) with 10% Fetal bovine serum (Thermo Fischer Scientific, USA). Trypsin EDTA, other molecular biology grade chemicals were obtained from SRL, India and Lipofectamine 2000 was obtained from Thermo Fischer Scientific (USA).
Computational Modelling and Insilico Docking studies
The identification of candidate proteins which can bind with high affinity to testosterone was carried out using a computational approach which is based upon the three-dimensional structure models of candidate proteins. The structures of selected GPCRs were modelled using I-TASSER software at server (https://zhanglab.ccmb.med.umich.edu/I TASSER/). All the generated models were subjected to PROCHECK to select the best model using the statistics of Ramachandran Plot. The models which displayed cut off greater than 97% of residues in favored regions and less than 3% residues in disallowed region were selected. The best models generated for candidate GPCRs were submitted to Protein Model Data Base (PMDB) at server (http://bioinformatics.cineca.it) and the PMDB IDs are (GPCR 205-PM0081560, GPCR 47-PM008561, GPCR 231-PM0081562, GPCR 232-PMOO81563, GPRC6A-PM0081564). The interaction studies of modelled GPCR with ligand testosterone was performed using Schrodinger Glide Maestro, USA software. 6 
Constructs
Human GPR56 NT (amino acids 1-510) and GPR56 CT (amino acids 511-693) were cloned into pcDNA3.1 between 5' Hind III 5'AGTGAAGCTTATGCCTCAGCCTCC-3' and Hind III site 5'-GTGCAGAAGCTTGGCACTGGCTCG-3' and GPR56 CT primers are 5'-TGCAAAGCTTCCTGCTCACCTGCC-3', 5'-GGTAAGCTTGAGGCCTAGATGCG-3' I626 and W623 double mutant receptor was generated using the following primers 5'-GCCTGCCCTGGGCCTTGATCTTCTTCTCCT-3' and 5'
GACCAGGCTGAGGCCCAGCAGTGTCAGCACA-3'. The mutant was generated using the Q5 ® Site-Directed Mutagenesis kit (NEB, catalog number #E0554S) according to the manufacturer's protocol. Reaction products were resolved on 2% agarose gel to determine the molecular sizes of the GPR56 amplicons. The gel images were obtained using BIO-RAD molecular imager.
RNA isolation and Reverse Transcription PCR
Western Blot Analysis
Whole cell lysate was prepared using cell lysis buffer containing 20mM Tris/HCl (pH 7.5), 
PKA Activation Assay
To check the androgen signaling and GPCR mediated PKA activation, HEK 293 cells were Chemiluminescence were detected by taking OD at 450 nm using ELISA Plate Reader. The OD 450 values were normalized with the average values obtained for GAPDH and the data was shown as the relative PKA activity compared to control.
Cyclic AMP Assay
Cells were seeded equally (5000 cells per well) in 96-well plates and allowed to grow overnight.
The HEK 293 cells and LNCaP cells were serum starved for 2-4 hour followed by stimulation with testosterone (10nM and 100nM) for 10 min at 37°C. Isoproterenol (10 M) was used as positive control in both cell lines. The cAMP assay was performed using the cAMP-Glo™ Assay Kit (Promega) according to the manufacturer's instructions. The assay was performed in triplicate and repeated three times.
Live Cell Imaging
LNCaP cells cultured in 100mm petridishes with cover slips and then transfected with GFP-AR plasmid on sterile glass with and without SiGPR56 (SiRNA against GPR56). The next day, cells were exposed to 10nM testosterone. Hoechst dye was used for nuclei staining. 
Luciferase Reporter Assay
LNCaP and HEK293 cells were cultured in media with 10% FBS and transfected using Lipofectamine 2000. Transfections were carried out with PSA-Luc plasmid (1µg). After 24 hours of transfection the cells were equally splitted in to 60mm petridishes and allowed to attach. After 24 hours, the identical cell population were treated with testosterone (0.1 and 10nM). Luciferase activities were measured with Luciferase assay kit (Promega) and were normalized with protein concentrations of samples.
Tissue Specimens
Twenty-five prostate tumor and matched normal tissues were obtained from radical prostatectomy specimens. This study was reviewed and approved by the Institutional Review Board (IRB) of Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India (586/SO/SKR-49). All methods were performed in accordance with the relevant guidelines and 11 regulations. Matched normal tissues were obtained from the lateral lobe of the same specimen.
Matched normal (N) and tumor tissue were stored in RNA Later at -80 0 C immediately after surgical excision. All patient's information was anonymized prior to analysis.
MTT Assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) assay was used to assess cell proliferation using the Cell Titer 96 ® AQ ueous One Solution Cell Proliferation kit, Promega, USA.
Cells were seeded in 96-well plates (5000 cells/well) for 1, 2, 3, and 4 days and 20 μL of assay reagent was added into the medium (as per the manufacturer's instructions) and incubated for 4 hours at 37 0 C in humidified 5% CO 2 incubator. The absorbance at 490 nm was measured on each day using ELISA plate reader (Lisa Plate Reader). Each experiment was repeated for at least three times.
Statistical Analysis
All statistical analysis was performed using Prism (Version 5.0) as detailed in the results. (p<0.05 was retained as a significance threshold). Data are expressed as mean ± SD. All statistical comparisons were made by using one-way ANOVA and two-way ANOVA test.
Results
1.Sequence comparison of mammalian GPCRs with the ligand binding domain (LBD) of AR
BLAST analysis was performed using the cDNA sequence of all (826) mammalian GPCRs and the sequence of Ligand Binding Domain (LBD) of AR. The candidates which demonstrated highest percentage identity (91 -100%) and query cover (26 -39 %) were shortlisted namely GPCR 205, GPCR 231, GPCR 232, GPCR 47, GPCR 708 and GPCR 675 (Table 1) . The identity and query cover of GPCRs 215 and 663 proposed as putative membrane androgen receptor The identity and query cover of two putative androgen responsive GPCRs identified earlier, namely, GPRC6A (23) and OXER1 (GPCR 663) (24) were also determined ( Table 1) . Models for selected GPCRs were designed using I-Tasser software ( Fig. 1A) , in absence of crystal structures and best models were selected through Ramachandran Plot (Fig. 1B ). GPCR 708 (containing 2367 amino acids) could not be modelled as its size was beyond the acceptable range of the I-Tasser software. Molecular docking using models of target proteins with testosterone (T) was carried out using the Schrodinger Glide Maestro, USA software ( Fig. 1 C) . GPCR 205 (GPR56) (27) exhibited the highest docking score of -8.3 Kcal (Table 2 ) and was used for further studies. The critical residues, capable of interacting with testosterone owing to their strategic location in the binding pocket include I626, W623, W563 and N574 and are displayed in residue interaction diagram (Fig. ID) . The residues I626 and W623 were capable of covalent interactions with testosterone and were therefore mutated into proline and arginine respectively, using site directed mutagenesis for verifying the interactions of testosterone with GPR56. A phylogenetic tree was also created to check the relatedness of the different GPCRs and AR (S 1 Fig) . GPR56 belongs to the adhesion G-protein coupled receptor family (28) and mutations in GPR56 result in a severe brain malformation known as bilateral frontoparietal polymicrogyria (BFPP) (27) . The known ligands of GPR56 in cultured cells includes collagen III, TG2 and heparin which activate downstream Rho signaling (29).
GPR56 expression in cell lines and membrane androgen binding
The adhesion GPCR family members are expressed in almost all-important organ systems of the body and play a role in neuronal functions, immunity, reproduction and development (30) . The expression of GPR56 at mRNA and protein levels was determined in three prostate cancer cell lines, namely, LNCaP, PC3, DU145 and two non-prostate cell lines, TM3 and HEK293 were chosen. RT-PCR analysis with RNA from these cell lines revealed that GPR56 was expressed in all these cell lines except HEK293 ( Fig. 2A ). Corresponding to this, GPR56 protein expression was observed in all prostate cell lines and two non-prostate cell lines TM3 and HEK293 (Fig.   2B ). Robust GPR56 protein expression was observed in LNCaP cells, which was reduced significantly upon transfection with GPR56 siRNA (Fig. 2C ). 16 To confirm the binding of testosterone to GPR56, flow cytometry was performed in LNCaP cells that express GPR56 mRNA. Correlating with the observed mRNA expression, LNCaP cells exhibited 88.3 % binding to T/BSA/FITC (Fig. 2D ). This binding was reduced by 69.2% upon transfection of the LNCaP cells with GPR56-SiRNA ( Fig. 2E ). There was no reduction in binding upon transfection of LNCaP cells with scrambled SiRNA (Fig. 2F) .
In (human) GPR56 transfected -HEK293 cells, incubation with T/BSA/FITC for 10 minutes caused 93.5 % binding whereas it was 13.6% in non-transfected cells ( Fig. 2G and H) correlating with negligible GPR56 mRNA expression observed in these cells. In HEK293 cells transfected with both GPR56 and GPR56 siRNA, T/BSA/FITC binding was 19.1 % while it was 94 % in cells transfected with GPR56 and scrambled siRNA ( Fig. 2I and J) . 
GPR56 mutants and FACS
To confirm that testosterone was indeed binding to the C-terminal domain of GPR56, as predicted by the bioinformatics analysis, GPR56 N-terminal (1 -509), C-terminal (511 -693) mutants and the double mutant (where Ile 626 & Trp 623 had been mutated) were also transfected into HEK 293 cells and FACS analysis was performed. Interestingly, binding of T-BSA-FITC to nontransfected HEK293 cells was negligible (Fig. 3A) , whereas binding to GPR56 was 99. 4 % (Fig.   3B ). The N-terminal mutant and the GPR56 double mutants also exhibited negligible binding ( Fig. 3C and D) , however, the GPR56 C-terminal exhibited 98.6 % binding, comparable with the binding of GPR56 wildtype (Fig. 3E ). The FACS results confirmed that testosterone bound to the C-terminal domain of GPR56 as predicted. transfected with scrambled siRNA (Sc GPR56) or siRNA against GPR56 (siGPR56), were treated or not treated with testosterone for 24 hrs. Total RNA was isolated and expression of PSA, an AR target gene was measured by RT-PCR, beta-actin was used as control.
GPR56 regulates AR transactivation
To investigate whether GPR56 activation could contribute to classical androgen receptor signaling, ARE-regulated transcription of luciferase reporter gene was measured in GPR56
expressing LNCaP cells. In these cells, treatment with 0.1nM and 10nM T stimulated AR activity 2.6 and 4 folds respectively. However, negligible activation was seen in LNCaP cells transfected with siRNA against GPR56 or PKA (Fig. 3F ). AR activity fold changes were same as in wildtype when scrambled siRNA was used (data not shown). Consistent with this, HEK293 cells overexpressing GPR56 exhibited five-fold increase in luciferase activity when treated with 10 nM T, compared to non-transfected cells (Fig. 3G) . Also, the luciferase activity of the HEK293 cells transfected with GPR56 N-terminal, C-terminal and double mutant were 1.7 folds, 5.3 folds and 2.6 folds respectively as compared to that transfected with vector alone (Fig. 3G ).
Further, we evaluated the effect of GPR56 knockdown on the transcription of PSA mRNA, as a prototype AR target gene in LNCaP cells. RT-PCR analysis demonstrated that PSA expression was robust in LNCaP cells and LNCaP transfected with GPR56 or scrambled siRNA but was reduced significantly in LNCaP cells transfected with GPR56 siRNA (Fig. 3H ).
Androgens activate PKA via GPR56
As GPR56 contributed to increased androgen transcription in prostate cells, it was apparent that androgen binding to GPR56 activated a downstream signaling pathway that contributed to classical androgen signaling. Since activation of PKA is a prerequisite step for AR transcription (31), we investigated whether testosterone treatment of GPR56 containing cell enhanced PKA.
Aberrant activation of PKA is observed in many CRPC patients (21) . Recently it has been demonstrated that activation of PKA is necessary for release of AR from HSP90 in the cytoplasm and its subsequent migration into the nucleus (31) . Also, in LNCaP cells that express GPR56, testosterone induced PKA activation was greater than three folds as compared to control, whereas in LNCaP cells transfected using GPR56-siRNA or PKA-siRNA, testosterone induced PKA activation was ~ 1.5 and 1.3 folds respectively (Fig. 4A ). Fold changes in PKA activity were same in wildtype when scrambled siRNA was used. (data not shown). In HEK 293 cells that do not express GPR56, negligible PKA activation was observed upon testosterone treatment, while greater than two-fold PKA activation was observed in HEK293 cells overexpressing GPR56 (Fig.   4B ). Isoproterenol (ISO), a known activator of PKA in these cells was used as a positive control.
PKA activation was also evaluated in HEK293 cells transfected using the GPR56 N-terminal, Cterminal or double mutant. A two-folds increase in PKA activity was observed in cells transfected with C-terminal and negligible change was observed in cells transfected with N-terminal and double mutant (Fig. 4B ).
PKA activation is usually a result of intracellular accumulation of cAMP (32) . However, a few studies have reported cAMP-independent activation of PKA (33, 34) . Stimulation of LNCaP cells or GPR56-transfected HEK293 using 10nM testosterone, for 10 min or 20 min, resulted in significant accumulation of cAMP in these cells ( Fig. 4C and 4D ), whereas cAMP accumulation was insignificant in GPR56 siRNA-transfected LNCaP cells or non-transfected HEK293 cells. 
GPR56 induces G 13 mediated Rho activation in cells
Previous studies have revealed that GPR56 mediates its actions by activating the Rho signaling pathway via activation of G 12/13 family of G-proteins (35, 36). To investigate whether testosterone mediated GPR56 activation also induces the Rho signaling pathway, HEK293 cells transfected with GPR56 were exposed to testosterone or vehicle alone (UT). Testosterone stimulation of GPR56-transfected HEK293 cells resulted in robust stimulation of Rho signaling pathway, as in case of positive control, whereas vehicle treatment caused negligible Rho activation (Fig. 5A ).
Rho activation was negligible upon testosterone treatment in HEK293 cells transfected using both GPR56 and Gα 13 siRNA demonstrating that testosterone induced Rho activation was mediated by the Gα 13 pathway (Fig. 5A) . Also, Rho activation was unaffected when HEK293 cells were transfected with GPR56 & scrambled siRNA and treated with testosterone ( Fig. 5A ). 
Rho activation in GPR56 mutants
Rho activation assay was also performed in HEK293 cells transfected with the GPR56 Nterminal and C-terminal mutants to ascertain whether the C-terminal part of GPR56 was indeed responsible for testosterone binding and stimulation, and also whether the GPR56 C-terminal part alone, was capable of inducing Rho activation. Cells were also transfected with the double mutant to ascertain their role in testosterone binding and Rho activation. Testosterone stimulation resulted in significant Rho activation in HEK293 cells transfected with GPR56 C-terminal and GPR56, while negligible Rho activation was observed in case of HEK293 cells transfected using GPR56 N-terminus or the GPR56 double mutant ( Fig 5B) .
GPR56 induced PKA activation is required for Rho activation
Our results demonstrated that both PKA and Rho pathways were triggered in GPR56 expressing cells upon exposure to testosterone. PKA activation is known to promote the barrier function of cellular tight junctions, however, PKA can produce different effects based on the cell type (37) .
Although cAMP/PKA seems to inhibit Rho activity in some cell types (38) , yet, Leve et al have demonstrated that PKA activation promotes Rho activation and regulates the reorganization of actin cytoskeleton (37) . To investigate whether testosterone-induced Rho activation was 22 influenced by PKA activation, HEK293 cells transfected with GPR56, GPR56 C-terminus and GPR56 N-terminus, and GPR56 double mutant were treated with PKA inhibitor H89 prior to testosterone stimulation and Rho activation assay was performed. Negligible Rho activation was observed in H89 treated cells indicating that testosterone induced PKA activation was important for Rho activation in these cells (Fig. 5B ).
GPR56 regulates the subcellular localization of AR
In prostate cells testosterone exposure induces the translocation of AR from cytosol to nucleus.
In LNCaP cells, transfected with GFP-tagged AR, most of the GFP-AR had translocated into the nucleus within 1 hour (Fig. 6A ). However, in LNCaP cells where GPR56 expression was knocked down using GPR56-siRNA, partial migration of GFP-AR was observed in the cytoplasm and nucleus after 1 hour (Fig. 6B ). Complete nuclear translocation of GFP-AR did not occur in these cells till 24 hours of testosterone treatment (S2 Fig) . Fig. 2 ). Nuclei were visualized by Hoechst staining. Scale bar,10um.
GPR56 induces cell growth and is over expressed in tumor samples
GPR56 has been proposed to play varying roles in tumor cell proliferation and metastasis (39) (40) (41) (42) . However, whether it accelerates the growth of tumor cells or not is still ambiguous. The MTT assay was performed in LNCaP and HEK293 cells to assess the role of GPR56 in cell 23 proliferation. The GPR56 siRNA transfected LNCaP cells, expressing negligible GPR56, exhibited significantly less cell growth compared to normal LNCaP cells, while overexpression of GPR56 in HEK293 cells increased cell proliferation compared to non-transfected HEK293 cells ( Fig. 7A and B) .
To investigate whether there is any difference in GPR56 expression in normal versus tumor 
Discussion
Endocrine therapies aimed at inhibiting AR function comprise the primary treatment plan for PCa patients. However, the tumor reappears in a more aggressive form due to the activation of alternate cellular pathways which directly or indirectly activate the AR and promote cell proliferation. Identification of novel signaling molecules/ pathways that may play a critical role in AR activation in cancerous prostate, is of utmost importance for developing new treatment strategies and drug targets for patients with advanced prostate cancer. Here we demonstrate androgen-mediated activation of adhesion GPCR, GPR56, that connects to classical AR signaling in prostate cells. A simple bioinformatics-based approach was used to identify GPCRs which exhibit maximum sequence similarity with the LBD of the AR. In spite of limitations associated with this approach, in absence of available crystal structures, structures were generated in silico and docking studies were performed to evaluate the possible interaction of these GPCRs with androgens. Binding of testosterone to GPR56 was most favorable energetically (-8.32 Kcal/mol) and hence GPR56 was subjected to further studies. Using the same software, the binding energies of GPRC6A (23) and GPCR 663 (24) , two other putative membrane ARs were -5.8 Kcal/mol and -5.011 Kcal/mol, respectively. The predicted binding site for testosterone is towards the Cterminus of the receptor, whereas that of collagen III and TG2, two known ligands of GPR56, is towards the N-terminus (42) (43) .
GPR56 is expressed in multiple tissues including muscle, liver, neural and cytotoxic lymphoid cells (27) . It plays a critical role in diverse processes including neural development and tumor metastasis (42) (43) . 25 In our studies binding of testosterone to GPR56 was assessed by flow cytometry in prostate cell lines such as LNCaP which express GPR56. Binding specificity was established by the fact that knocking down the GPR56 expression in LNCaP cells by transfecting GPR56 siRNA, significantly reduced binding of T-BSA-FITC to these cells. To confirm that testosterone actually bound to the C-terminal domain of GPR56, a C-terminal clone that included only the residues predicted to bind to testosterone (511 -695) and an N-terminal construct (1 -509) including the entire protein excluding the testosterone binding domain were generated (Fig. 8A) . Interestingly, only the C-terminal fragment and GPR56 exhibited strong binding to T-BSA-FITC while the Nterminal construct representing the N-terminal part, GAIN domain and most of the 7TM domain, exhibited negligible binding. Also, the double mutant in which two critical testosterone binding residues, namely, Ile 626 and Trp 623 had been altered showed negligible binding to testosterone confirming the key role of these residues in testosterone binding.
Multiple Sequence Alignment was performed to assess the conservation of Ile 626 and Trp 623 in GPR56 from different species and also among adhesion GPCRs of family VIII to which GPR56 belongs (Table 3 and (highlighted in red) and W563 (highlighted in green) of GPR56 involved in making good interaction with testosterone are highly conserved in all adhesion GPCRs of group VIII. 27 The Ile 626 was replaced by another nonpolar amino acid residue Valine in other species (or Glycine in one species) whereas the Trp 623 remained unchanged in all species studied. This is in agreement with earlier analysis by Graaf et al, (44) and points to the importance of these residues in GPR56 function. Also, our study provides the first example of a ligand binding to the C-terminal domain of GPR56. Earlier studies by Pi et al have demonstrated that testosterone binds towards the C-terminal end of GPRC6A, another membrane GPCR (45) . The critical residues of GPR56 as well as GPRC6A, predicted to bind to testosterone, belong to transmembrane domains, TM5 and TM6 (45) . The TM6 of the 7TM plays an important role in receptor activation, as it moves away from the transmembrane bundle to aid G-protein activities (46) . However, as the Ile and Trp residues, predicted to interact with testosterone are included in TM6, it would be interesting to investigate the mechanism of testosterone binding and subsequent Although testosterone did not bind to the N-terminal of GPR56, yet, it stimulated the Rho 28 pathway like the other GPR56 ligands. Notably, PKA activation was necessary for Rho activation by testosterone as inhibiting PKA activation by H89 inhibited Rho activation. Binding of testosterone to GPRC6A also activates both PKA and MAP kinase signaling pathways and PKA activation is necessary for testosterone-induced ERK activation (45) .
Testosterone exposure also triggered rapid activation of both cAMP and PKA levels that is reduced to near-basal levels in GPR56-siRNA transfected cells. Though cAMP and PKA activation are mostly a consequence of activation of Gαs signaling axis, yet a few instances have revealed G 13 mediated activation of cAMP through adenylate cyclase 7 (47) . Whether the cAMP/PKA activation by testosterone-stimulation of GPR56 is G αs or G 13 mediated would require detailed studies.
Previous studies have shown that PKA activation is a prerequisite step for phosphorylation of HSP90 bound to unliganded AR. This causes release of AR and its nuclear migration (31) .
Knocking down the expression of GPR56 or PKA in LNCaP cells using respective siRNA reduces the AR transcription significantly. Also, in HEK 293 cells transfecting GPR56 along with AR enhances transcription, AR transcription is minimal when these cells are co-transfected with GPR56 N-terminal or GPR56 double mutant.
Also, as expected, knockdown of GPR56 expression, led to sequestration of AR in the cytoplasm.
While most of the AR had translocated into the nucleus within 1 hour in LNCaP cells, the import of GFP-AR in cells transfected with si-GPR56 took much longer and was only partial even after 24 hours of treatment. In keeping with this, lowering of GPR56 expression using siRNA caused a reduction in ARE-regulated reporter gene activity as well as reduction in expression of PSA, an AR target gene. 29 Based on our findings and earlier reports existence of parallel androgen effector pathways seem imminent, this non-genomic pathway mediated via GPR56 (and possibly other GPCRs) that activates cAMP and PKA and a genomic pathway that is mediated through the nuclear AR by direct binding of androgens (Fig.8B ). Activation of both these pathways is required for complete androgen signaling. Thus, activation of GPCRs such as GPR56 by androgens is necessary for activating the PKA pathway that uncouples the AR from HSP90, so that it can migrate into the nucleus to execute its functions.
What could be the physiological role of androgen binding to GPR56? Although much is known about GPR56 function in brain, yet, comparatively little is revealed about its role in other organs such as the prostate. Some of the effects of androgens in brain and other organs could be mediated by GPR56. Androgens play a critical role in neuron myelination in mice and castration impairs recruitment of astrocytes to axons (48) . GPR56 too is a regulator of oligodendrocyte development and regulates myelin sheath formation (49) . The effect of androgens on myelin sheath formation could be mediated by GPR56. Overexpression of the C-terminal domain of GPR56 causes increased secretion of VEGF in melanoma cells (50) . Androgens enhance VEGF expression both at the RNA and protein level (51) . Whether androgen binding to the C-terminal domain of GPR56, plays a role in increased VEGF secretion needs further investigation.
Our study demonstrates that extensive positive cross talk exists between the genomic and nongenomic mode of AR signaling. While androgens activate GPR56 resulting in activation of PKA and Rho signaling pathways, activated PKA in turn is necessary for classical AR signaling. Thus, in CRPC patients, who have low concentrations of androgen, aberrant activation of GPR56 or PKA inside the cell by agents other than androgens can trigger AR activation (52) . This could be a major reason for the failure of endocrine therapies in CRPC patients (3) . Of the twenty-five prostate tumor samples that we investigated, GPR56 mRNA expression was higher in all samples tested revealing its possible involvement in tumor cell proliferation. To validate, two different sets of primers were used for analyzing GPR56 expression in patient samples, The role of GPR56 as a membrane androgen receptor is strengthened by the fact that mice lacking GPR56 expression (GPR56 -/-) show impaired or no testes development (52) . The precise role of GPR56 in male reproduction and prostate cancer development needs to be established. 31 Currently, GPCRs represent the single largest drug target as they recognize a wide variety of ligands and are found almost ubiquitously in the body (53) . Development of antagonists and drug targets against GPR56 may be effective in limiting prostate tumor growth, however such targets need to be designed carefully, so that the positive role of GPR56 in brain development is not compromised. Further studies are required to completely elucidate the role of GPR56 as a membrane androgen receptor and its function in different organs of the body. 
